-
Kangtai Biological Subsidiary received the notification of on-site verification of the registration of freeze-dried human rabies vaccine
Time of Update: 2022-02-18
On January 24, Kangtai Biological announced that the company's wholly-owned subsidiary, Minhai Biological, has recently received a CDE notice that it needs to start drug registration verification for the freeze-dried human rabies vaccine (human diploid cells) declared and registered by Minhai Biological.
Freeze-dried human rabies vaccine (human diploid cells) for the prevention of rabies .
-
The application for the clinical trial of BC004 for injection, a subsidiary of Buchang Pharmaceutical, was accepted
Time of Update: 2022-02-18
(referred to as "Luzhou Buchang") was accepted by the State Drug Administration and received.
to the "Notice of Acceptance" .
As of December 31, 2021, Luzhou Buchang has invested approximately RMB 48.
-
New drug for atopic dermatitis!
Time of Update: 2022-02-18
TREK-AD is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical study to evaluate the efficacy and safety of eblasakimab in adult patients with moderate to severe AD who are candidates for systemic therapy .
-
Promising to improve standard treatment of psoriatic arthritis!
Time of Update: 2022-02-18
On January 21, 2022, UCB (UCB) announced that the second Phase 3 clinical trial of the IL-17A/F inhibitor Bimzelx (bimekizumab) in the treatment of active psoriatic arthritis (PsA) achieved positive top-line results .
Retrieved January 21, 2022, from https:// article/Positive-Top-Line-Results-for-BimzelxRVbimekizumab-in-Second-Phase-3-Psoriatic-Arthritis-Study[2] Bimekizumab Overview.
-
Announcement of Phase Ib clinical results of sintilimab combined with bevacizumab in the treatment of advanced hepatocellular carcinoma
Time of Update: 2022-02-18
Innovent and Eli Lilly jointly announced the final clinical study results and biomarker analysis of Dabosu® (sintilimab injection) in combination with bevacizumab in the treatment of advanced hepatocellular carcinoma (NCT04072679) in Phase Ib (NCT04072679).
-
The traditional Chinese medicine sector is becoming the focus of institutional investigations!
Time of Update: 2022-02-18
Yiling Pharmaceutical released a record of investor relations activities on January 20, and the company received surveys from 44 institutions on January 19, 2022 .
Xintian Pharmaceutical released a record form of investor relations activities on January 7, and the company received 46 institutional investigations on January 6, 2022 .
-
In 2021, a large number of multinational pharmaceutical companies will spend huge amounts of money on TV advertising
Time of Update: 2022-02-18
The drug with the largest increase in ad spending on the list is Johnson & Johnson's anti-inflammatory drug Tremfya .
In addition to Tremfya, AbbVie's oral JAK inhibitor Rinvoq has also increased year-on-year in advertising spending, rising from $122.
-
AI pharmaceuticals are still making great progress, and domestic financing is showing explosive growth
Time of Update: 2022-02-18
Behind the popularity of AI pharmaceuticals, pharmaceutical companies are facing increasing challenges, including the rising cost of new drug research and development year by year, and the increasingly fierce market competition .
-
10 big deals in the pharmaceutical industry this week
Time of Update: 2022-02-18
Zhangzhou Shengli East Road Securities Sales Department; On January 20th, a large transaction occurred in Pien Tze Huang, with a total transaction of 21,000 shares, the transaction amount was 8.
-
Under the strategic adjustment, the pharmaceutical company plans to fire 50% of its executives
Time of Update: 2022-02-17
In addition to Zymeworks, some pharmaceutical companies have recently announced layoffs .
In general, the layoffs, personnel changes, and business adjustments of pharmaceutical companies are actually one of the responses made by pharmaceutical companies in response to the changes in the future pharmaceutical industry .
-
When the development of biopharmaceuticals is right, the growth space of upstream equipment and consumables will be opened
Time of Update: 2022-02-17
When the development of biopharmaceuticals is just in time, the growth space of upstream equipment and consumables will be opened (Photo source: Pharmaceutical Network) It is worth mentioning that at present, China has carried out six batches of centralized procurement, and the scope of centralized drug procurement has also expanded from drugs and consumables to detection reagents, biological medicine .
-
Chinese medicine DRG may become the general trend, the industry: Chinese medicine industry should say goodbye to barbaric growth!
Time of Update: 2022-02-17
On December 30, 2021, the National Medical Insurance Administration and other two departments jointly issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine", which pointed out that "TCM medical institutions may temporarily not implement DRG payment.
-
In 2022, how will the demand of various downstream sub-industries of pharmaceutical equipment change?
Time of Update: 2022-02-17
Relevant statistics show that in 2020, the main business income of China's traditional Chinese medicine decoction pieces processing industry is about 160 billion yuan, a decrease of more than 30 billion yuan from 193.
-
In the pharmaceutical industry, a batch of positive and negative announcements...
Time of Update: 2022-02-17
Aibo Medical released the 2021 annual performance forecast in the evening: It is expected that the net profit attributable to the owners of the parent company in 2021 will be 160 million to 180 million yuan, and Compared with the same period of last year (statutory disclosure data), it will increase by 65.
-
The disclosure of the annual report performance forecast of the pharmaceutical company was just in time, and another CRO company expected a substantial increase in performance
Time of Update: 2022-02-17
On January 24, Boji Pharmaceutical released the 2021 annual report performance forecast, saying that it is expected to achieve a net profit of 37 million to 48 million yuan from 2021-01-01 to 2021-12-31, an increase of 117.
-
A group of pharmaceutical companies are performing marriage and breakup dramas!
Time of Update: 2022-02-17
For example, on January 23, Betta Pharmaceuticals announced that the company's wholly-owned subsidiary, Betta Biopharmaceuticals, planned to invest 76 million yuan to acquire Zhejiang Shimai Pharmaceutical Co.
-
The prospect of innovative traditional Chinese medicine is still optimistic
Time of Update: 2022-02-17
In addition, Fangsheng Pharmaceutical also stated to the relevant media not long ago that it will continue to increase investment in the research and development of innovative traditional Chinese medicine drugs .
-
In 2022, the "cooperation tide" of pharmaceutical companies has begun to rise
Time of Update: 2022-02-17
On the 11th, Fosun Pharma and Insilico Medicine also announced a cooperation agreement to jointly promote the research and development of AI drugs for multiple targets worldwide.
-
In less than a month, the executives of 13 pharmaceutical companies have changed!
Time of Update: 2022-02-17
Shengxiang Bio: Deputy General Manager Resigns On January 6, Shengxiang Bio announced that the board of directors recently received a written resignation report from the company's deputy general manager Gui Yaokui, who applied for his resignation as the company's deputy general manager for personal reasons.
-
Within a month, 430 institutions intensively investigated this pharmaceutical company!
Time of Update: 2022-02-17
Specifically, there are four important directions worthy of attention, including: the growth of the in vitro diagnostic business will accelerate; the company will continue to support the new medical infrastructure on a global scale, continue to achieve breakthroughs in high-end hospitals and increase the penetration rate, and expand brand influence; orthopedics and Some IVD products have benefited from the influence of centralized procurement, DRGS and other policies in some regions, and the market coverage and share have been accelerated.
